Ryzodeg

RSS

insulin degludec / insulin aspart

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Ryzodeg. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Ryzodeg.

This EPAR was last updated on 23/09/2021

Authorisation details

Product details
Name
Ryzodeg
Agency product number
EMEA/H/C/002499
Active substance
  • insulin aspart
  • insulin degludec
International non-proprietary name (INN) or common name
  • insulin degludec
  • insulin aspart
Therapeutic area (MeSH)
Diabetes Mellitus
Anatomical therapeutic chemical (ATC) code
A10AD06
Publication details
Marketing-authorisation holder
Novo Nordisk A/S
Revision
13
Date of issue of marketing authorisation valid throughout the European Union
21/01/2013
Contact address
Novo Allé
DK-2880 Bagsværd
Denmark

Product information

15/07/2021 Ryzodeg - EMEA/H/C/002499 - IB/0047/G

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Drugs used in diabetes

Therapeutic indication

Treatment of diabetes mellitus in adults, adolescents and children from the age of 2 years.

Assessment history

Related content

How useful was this page?

Add your rating
Average
2 ratings
1 rating